Evaluating the Safety of a Rotavirus Vaccine
Author Information
Author(s): Heyse Joseph F, Kuter Barbara J, Dallas Michael J, Heaton Penny
Primary Institution: Merck Research Laboratories
Hypothesis
Does the rotavirus vaccine RotaTeq increase the risk of intussusception compared to a placebo?
Conclusion
The study found that the risk of intussusception was similar in both vaccine and placebo recipients, and the vaccine effectively prevented rotavirus gastroenteritis.
Supporting Evidence
- The study involved approximately 70,000 infants at over 500 study sites in 11 countries.
- The vaccine prevented rotavirus gastroenteritis and reduced hospitalizations.
- The risk of intussusception was similar in vaccine and placebo recipients.
Takeaway
The study tested a new rotavirus vaccine on many babies to see if it caused a rare bowel problem, and it didn't, while also helping to prevent a common stomach illness.
Methodology
A blinded, placebo-controlled study involving approximately 70,000 infants across over 500 sites in 11 countries.
Limitations
The study primarily focused on intussusception and may not have captured all potential adverse events.
Participant Demographics
Over 35,000 infants (50%) were from the United States.
Statistical Information
Confidence Interval
Upper bound of the 95% confidence interval for relative risk of intussusception was ≤10.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website